Michael LaPelusa, Hematologist and Medical Oncologist at MidAmerica Cancer Care, shared on X:
“On September 23, an FDA advisory committee will review a Premarket Approval application from GRAIL for its Galleri multi-cancer early detection (MCED) test. It will be the first time an MCED test gets reviewed by such a committee.
What do you expect?
- Favorable vote
- Unfavorable vote
- Too close too call.
Before Stage One / Post 10 – Regulation and Reimbursement.
Before Stage One / Post 12 Journal Club: NHS-Galleri (GRAIL).
This also can be interesting: New Paper Alert: Advancements in Multi-Cancer Early Detection. The Role of Liquid Biopsy and AI in Cancer Prevention
